Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence
Rena Feinman(Georgetown University), Andrew L. Pecora(Hackensack University Medical Center), Lori A. Leslie(Hackensack University Medical Center), Alan P Skarbnik(Novant Health), Tatyana Feldman(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Robert Korngold(Georgetown University), Noa Biran(Hackensack University Medical Center), Michael B. Atkins(Georgetown University), Pashna N. Munshi(Johns Hopkins Hospital), Suzanne Kosky(Hackensack Meridian Health), Scott D. Rowley(Johns Hopkins Hospital), Iriana Colorado(Hackensack Meridian Health), Joshua Zenreich(Hackensack University Medical Center), Tracy Andrews(Rutgers, The State University of New Jersey), André Goy(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), David H. Vesole(Hackensack University Medical Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k